The early-stage company has the potential to provide significant returns, as it pioneers cutting edge technology for human and animal biopharma manufacturing.
Its game-changing microbial contamination detection solution is poised to revolutionize an entire industry.
• The company’s biologics in-process manufacturing microbial contamination detection market has an estimated annual TAM of ~$2.0 billion.
• The company presents an opportunity to save biopharma companies millions of dollars.
• The market need has been confirmed by feasibility studies and market research with leading biopharma manufacturers.
In its current state, this system has a broader spectrum, and is faster and easier to use than existing microbial contamination detection products. This funding round secures the capital needed to build the 2nd Generation System needed to meet biopharma manufacturing’s specific needs.
Thank you for subscribing to Insider Trades Daily, which covers the most recent insider buying and selling activity from Wall Street CEO's, CFO's, COO's and other insiders.
This message is a paid advertisement sent on behalf of LexaGene, a third-party advertiser of InsiderTrades.com and MarketBeat.
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.
Post a Comment
Post a Comment